180 related articles for article (PubMed ID: 12456326)
1. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.
Carpentier AF; Auf G; Delattre JY
Front Biosci; 2003 Jan; 8():e115-27. PubMed ID: 12456326
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma.
Ursu R; Carpentier AF
Adv Exp Med Biol; 2012; 746():95-108. PubMed ID: 22639162
[TBL] [Abstract][Full Text] [Related]
3. [Cancer immunotherapy with CpG-ODN].
Carpentier AF
Med Sci (Paris); 2005 Jan; 21(1):73-7. PubMed ID: 15639024
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
Jahrsdörfer B; Weiner GJ
Semin Oncol; 2003 Aug; 30(4):476-82. PubMed ID: 12939716
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
6. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
[TBL] [Abstract][Full Text] [Related]
9. TLR ligands in the local treatment of established intracerebral murine gliomas.
Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
[TBL] [Abstract][Full Text] [Related]
10. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.
Decker T; Peschel C
Leuk Lymphoma; 2001 Jul; 42(3):301-7. PubMed ID: 11699394
[TBL] [Abstract][Full Text] [Related]
11. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
Miles SA; Sandler AD
Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
[TBL] [Abstract][Full Text] [Related]
13. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
Weiner GJ
Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
[TBL] [Abstract][Full Text] [Related]
14. Use of CpG oligonucleotides in treatment of asthma and allergic disease.
Fonseca DE; Kline JN
Adv Drug Deliv Rev; 2009 Mar; 61(3):256-62. PubMed ID: 19167442
[TBL] [Abstract][Full Text] [Related]
15. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.
Verthelyi D; Gursel M; Kenney RT; Lifson JD; Liu S; Mican J; Klinman DM
J Immunol; 2003 May; 170(9):4717-23. PubMed ID: 12707351
[TBL] [Abstract][Full Text] [Related]
17. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in weaned piglets.
Zhang L; Tian X; Zhou F
Int Immunopharmacol; 2006 Oct; 6(10):1623-31. PubMed ID: 16919835
[TBL] [Abstract][Full Text] [Related]
19. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
Warren TL; Weiner GJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):93-7. PubMed ID: 11842395
[TBL] [Abstract][Full Text] [Related]
20. CpG motifs as possible adjuvants for the treatment of allergic diseases.
Bohle B
Int Arch Allergy Immunol; 2002 Nov; 129(3):198-203. PubMed ID: 12444316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
